GlassScriptPhysician profile
Vera Rymsha Mcghee
NPI 1093160343
$1,279.43
in general payments reported to CMS, 2019-2025
25 companies · $126 in 2025
The $126 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $242 · 2023: $330 · 2024: $581 · 2025: $126.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,037.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,037.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $238.01 | 2022-2024 | Wakix |
| Electromed, INC. | $132.38 | 2024 | Smartvest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $110.62 | 2022-2024 | Ofev |
| Astrazeneca Pharmaceuticals LP | $91.46 | 2022-2024 | Andexxa, Breztri, Fasenra |
| Abbvie INC. | $85.72 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $72.79 | 2023-2024 | Zerbaxa, Recarbrio |
| Jazz Pharmaceuticals INC. | $60.07 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $49.14 | 2024-2025 | Eliquis |
| Alexion Pharmaceuticals, INC. | $38.38 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.77 | 2023-2025 | Xifaxan |
| La Jolla Pharmaceutical Company | $35.65 | 2022-2023 | Giapreza |
| Pfizer INC. | $32.81 | 2022-2023 | |
| Mylan Specialty L.P. | $31.92 | 2022-2023 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $29.47 | 2024 | Glassia |
| Ani Pharmaceuticals, INC. | $29.15 | 2023 | Purified Cortrophin Gel |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $28.65 | 2024 | Hillrom - Monarch Airway Clearance System |
| Bayer Healthcare Pharmaceuticals INC. | $28.07 | 2022 | |
| Resmed Corp | $22.20 | 2024 | |
| Actelion Pharmaceuticals US, INC. | $21.92 | 2024 | Opsumit, Uptravi |
| Melinta Therapeutics, LLC | $20.25 | 2024 | Vabomere, Rezzayo |
| United Therapeutics Corporation | $19.03 | 2022 | |
| Mallinckrodt Hospital Products INC. | $18.05 | 2025 | Terlivaz |
| Genentech USA, INC. | $16.82 | 2023 | Xolair |
| Glaxosmithkline, LLC. | $16.53 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $14.57 | 2025 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vera Mcghee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.